Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylnaltrexone bromide - Progenics Pharmaceuticals/Bausch Health Companies

Drug Profile

Methylnaltrexone bromide - Progenics Pharmaceuticals/Bausch Health Companies

Alternative Names: Methyl-naltrexone hydrobromide; Methylnaltrexonium; MNTX; MNTX 302; MOA-728; MRZ 2663BR; MRZ-2663; N-methylnaltrexone bromide; Naltrexone MB; Naltrexone methobromide; Naltrexone methylbromide; Naltrexonium methiodide; ONO-3849; Quaternary ammonium naltrexone; Relistor; Relistor Oral

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Chicago
  • Developer Glycyx Pharma Ventures; Ono Pharmaceutical; Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Class Morphine derivatives; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Marketed Constipation
  • Research Pancreatic cancer
  • Discontinued Postoperative ileus; Urination disorders

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 02 May 2018 Valeant Pharmaceuticals has validity of formulation patent protection for methylnaltrexone bromide in USA
  • 15 Mar 2017 Glycyx PharmaVentures and Valeant Pharmaceuticals enter into a license agreement for Oncology indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top